Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

Part of paid clinical trials in Idaho Falls, Idaho.

Sponsor
Carla Greenbaum, MD
Study ID
NCT03632759
Phase
EARLY_PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Participants will receive subcutaneous (SC) liraglutide for 8 weeks
  • Golimumab — DRUG
    Participants will receive subcutaneous (SC) golimumab for 8 weeks

Study Details

The purpose of this study is to determine whether 8 weeks of Liraglutide or Golimumab can transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D) who secrete proinsulin and little/no C-peptide.

Key Dates

First listed
Aug 15, 2018
Start date
Aug 15, 2018
Status verified
Jan 2022
Primary completion
Nov 9, 2021
Completion
Nov 9, 2021

Study Design

Enrollment
16 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Liraglutide
    Participants will receive subcutaneous (SC) liraglutide for 8 weeks
  • Experimental: Golimumab
    Participants will receive subcutaneous (SC) golimumab for 8 weeks

Primary Outcome Measure

Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL. [ Time Frame: 0-to-8 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
Rocky Mountain Diabetes and Osteoporosis CenterIdaho FallsIdaho83404-
Benaroya Research InstituteSeattleWashington98101-

Find similar trials in Idaho Falls, ID

Nationwide
Type 1 diabetes trialsEndocrinology trials
By condition
Type 1 diabetes
By specialty
Endocrinology
By research site
Rocky Mountain Diabetes and Osteoporosis Center· Idaho Falls, IDBenaroya Research Institute· Seattle, WA

Related Studies